Synopsis

Source of validity: Scientific
Rating (out of 5): 5

Calcium folinate (also known as leucovorin) is scientifically validated for use in leukemia, particularly in the context of chemotherapy. Its primary role is as a "rescue" agent following high-dose methotrexate therapy, a common chemotherapeutic agent used in the treatment of acute lymphoblastic leukemia (ALL) and other cancers. Methotrexate inhibits dihydrofolate reductase, blocking folate metabolism and DNA synthesis, which affects both cancerous and normal cells. Calcium folinate is a reduced form of folic acid that can bypass this blockage, "rescuing" normal cells from methotrexate-induced toxicity without diminishing the anti-leukemic effect of methotrexate on malignant cells.

There is robust clinical evidence and established guidelines supporting the use of calcium folinate rescue in leukemia treatment protocols. Numerous randomized controlled trials and decades of clinical practice have demonstrated that calcium folinate significantly reduces the risk of life-threatening toxicity (such as bone marrow suppression and mucositis) associated with methotrexate therapy, improving patient outcomes and allowing for higher, more effective methotrexate dosing. It is not used as a direct anti-leukemic agent, but as an essential adjunct to enhance the safety and efficacy of chemotherapy. Leading oncology guidelines (e.g., NCCN, ASCO) recommend its use, and it is considered standard of care in modern leukemia treatment regimens involving methotrexate.

More about Vitamin B9 (Calcium Folinate)
More about Leukemia

Other ingredients used for Leukemia

Other health conditions supported by Vitamin B9 (Calcium Folinate)

Products containing Vitamin B9 (Calcium Folinate)